News | Cath Lab | November 09, 2017

Supersaturated Oxygen Therapy Reduces Infarct Size for High-Risk Stented AMI Patients

TherOx IC-HOT study meets primary endpoint for improved patient outcomes

Supersaturated Oxygen Therapy Reduces Infarct Size for High-Risk Stented AMI Patients

November 9, 2017 — TherOx Inc. announced that results of its IC-HOT (Evaluation of Intracoronary Hyperoxemic Oxygen Therapy) study successfully met its primary endpoint. The purpose of this study was to confirm the safety and effectiveness of Supersaturated Oxygen (SSO2) Therapy in treatment of anterior acute myocardial infarction (AMI) patients who have undergone successful percutaneous coronary intervention (PCI) with stenting within six hours of experiencing AMI symptoms. These results are included in the Premarket Approval (PMA) application for the SSO2 Therapy system that has been accepted for filing by the U.S. Food and Drug Administration (FDA).

The study results were presented at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Oct. 29-Nov. 2 in Denver.

“Supersaturated oxygen is the only therapy shown in a pivotal randomized trial to reduce the important endpoint of infarct size in patients with large myocardial infarction,” said Gregg W. Stone, M.D., principal investigator of the IC-HOT study and professor of medicine at Columbia University Medical Center. “The IC-HOT study, using a simpler delivery method than previously tested, demonstrated that use of supersaturated oxygen is safe after successful primary stenting in high-risk patients with anterior myocardial infarction.”

IC-HOT is a confirmatory study of the second-generation TherOx system that delivers SSO2 Therapy for reduction of infarct size after an AMI. The study enrolled 100 patients at 15 investigational centers in the United States. IC-HOT results build on the successful outcome of the AMIHOT II controlled, randomized pivotal trial that studied the first-generation SSO2 Therapy system, and combined these study results to provide the FDA with the basis for PMA approval.

SSO2 Therapy is intended to provide interventional cardiologists with the first treatment option beyond PCI to salvage heart muscle in heart attack patients. Although PCI is the standard of care in treating AMI, for many patients it does not sufficiently reduce infarct size to achieve maximum clinical benefit. In SSO2 Therapy, the patient’s blood is supersaturated with oxygen and then returned directly to the targeted ischemic area of the heart through a small catheter. Adjunctive to PCI, SSO2 Therapy is intended to salvage heart muscle and reduce infarct size.

Find links to articles and videos for all the key presentations in the article "TCT 2017 Late-breaking Clinical Trial Presentations."
 

 

For more information: www.therox.com

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init